Furtherly, since FXa is the direct activator of prothrombin, this strategy might also be effective in the treatment of other bleeding disorders due to insufficient FXa induced by coagulation factors, such as the deficiency of factor VII and FX and the Type 3 von Willebrand disease. The gene discussed is F7; the disease is hemorrhagic disease.